BPG is committed to discovery and dissemination of knowledge
Featured Articles
6/15/2026 9:55:14 AM | Browse: 154 | Download: 777
Publication Name World Journal of Nephrology
Manuscript ID 117073
Country Pakistan
ISSN 2220-6124 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Transplantation
Manuscript Type Review
Article Title Lupus nephritis and kidney transplantation: A narrative review of patient and graft outcomes
Manuscript Source Invited Manuscript
All Author List Tabassum Elahi, Saima Ahmed and Muhammed Mubarak
Funding Agency and Grant Number
Corresponding Author Tabassum Elahi, Professor, Department of Nephrology, Sindh Institute of Urology and Transplantation, Chand Bibi Road, Karachi 74200, Sindh, Pakistan. elahitabassum@gmail.com
Key Words End-stage kidney disease; Graft survival; Immunosuppressive therapy; Kidney transplantation; Lupus nephritis; Outcomes
Core Tip Kidney transplantation is the preferred treatment for lupus nephritis progressing to end stage kidney disease, though its survival benefit in lupus nephritis end-stage kidney disease remains uncertain. Achieving disease quiescence before transplantation is critical, yet emerging evidence supports preemptive transplantation and personalized immunosuppressive regimens to enhance outcomes. New therapies such as voclosporin and belimumab, together with biomarkers like urinary monocyte chemoattractant protein-1, matrix metallo proteinase-7and B-cell activating factor, show promise for improving patient selection, monitoring disease activity, and predicting recurrence. Careful integration of updated guidelines and recent evidence is essential to optimize both patient and graft survival.
Publish Date 2026-06-15 08:38
Citation

Elahi T, Ahmed S, Mubarak M. Lupus nephritis and kidney transplantation: A narrative review of patient and graft outcomes. World J Nephrol 2026; 15(2): 117073

URL https://www.wjgnet.com/2220-6124/full/v15/i2/117073.htm
DOI https://doi.org/10.5527/wjn.v15.i2.117073
Full Article (PDF) WJN-15-117073-with-cover.pdf